<DOC>
	<DOCNO>NCT01313143</DOCNO>
	<brief_summary>Pharmacokinetics , pharmacodynamics tolerability AOP200704 infusion compare Esmolol measurement plasma concentration AOP200704 , esmolol metabolite , assess effect drug dobutamine-induced tachycardia , monitor vital sign , ECG adverse event .</brief_summary>
	<brief_title>A Short Term Pharmacokinetic , Pharmacodynamic Tolerability Study Compare AOP200704 vs. Esmolol</brief_title>
	<detailed_description>16 healthy volunteer sex , age 18 45 year , enrol . The mean dose necessary suppress Dobutamine induce heart rate increase least 30 bpm baseline rate ( maximum heart rate app . 110 bpm ) least 20 bpm calculate AOP200704 Esmolol dose/efficacy relation agent calculate steady state condition . For drug time reach decrease 10 bpm , 20 bpm maximum effect calculate . In addition mean time increase 10 20 bpm time reach maximum heart rate ( increase 30 bpm baseline ) termination infusion also assess drug . Blood pressure value compare mention time point heart rate assess pharmacodynamics.The study consist screening , cross-over 1 , cross-over 2 end-of-study visit .</detailed_description>
	<mesh_term>Esmolol</mesh_term>
	<criteria>Male female human subject , age 1845 year Body weight least 50 kg , maximum 90 kg . Bodymass index 18.5 30.0 kg/m2 Caucasians Subjects without clinically relevant abnormality Subjects agree use prescription counter medication include vitamin mineral 7 day prior study course study No drug alcohol abuse Nonsmokers , ex smoker mild smoker Subjects history presence clinically relevant cardiovascular , renal , hepatic , ophthalmic , pulmonary , neurological , metabolic , hematological , gastrointestinal , endocrine , immunological , psychiatric skin disease . Subjects bradycardia ( heart rate 50 bpm ) , tachycardia ( heart rate 100 bpm ) , hypotension ( systolic blood pressure 100 mmHg , and/or diastolic blood pressure 70 mm Hg ) screening , clinically relevant history clinically relevant arrhythmias Subjects clinically relevant cardiac supraventricular ventricular arrhythmia . Subjects atrioventricular block grade II III , sick sinus syndrome , sinoatrial block congestive heart failure Participation clinical drug study bioequivalence study 60 day prior present study . History malignancy serious disease . Any contraindication blood sample . History i.v . drug abuse . Subjects positive HIV test , HBsAg Hepatitis C test acute , subacute chronic infectious disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>AOP200704 , Esmolol , Pharmacokinetics , Pharmacodynamics</keyword>
</DOC>